Brought to you by 
AstraZeneca gets Chinese rights to Cubicin from Cubist
03 Jan 2007
Executive Summary
AstraZeneca has licensed from Cubist Pharmaceuticals (anti-infective therapeutics) rights to develop and sell the lipopeptide antibiotic Cubicin (daptomycin for injection) in China and certain countries in the Middle East, Asia (excluding Japan), and Africa that are not already covered under existing license agreements.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AstraZeneca gets Chinese rights to Cubicin from Cubist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice